https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/accelerated-approval-request-new-drug-rare-childhood-muscle-disorder/
Accelerated approval request for a new drug for a rare childhood muscle disorder
9 Sep 2015, 4:41 p.m.
A drug for Duchenne Muscular Dystrophy (DMD), originally developed by BRC Theme Lead Professor Francesco Muntoni’s Consortium in the UK, has been filed by Sarepta Therapeutics for accelerated approval by the United States Food and Drug Adminstration (FDA).The drug Eteplirsen is an antisense oligonucleotide that is designed to enable the production of a functional truncated dystrophin protein to alleviate some of the symptoms of DMD.
DMD is an X-linked rare degenerative neuromuscular disorder that causes severe progressive muscle loss and premature death. It is one of the most common fatal genetic disorders, affecting approximately one in every 3,500 boys born worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fibre function. The condition is universally fatal, and death usually occurs before the age of 30.
The findings from the original study were reported in the Lancet in 2011. The first patient to receive the systemic injection of this novel compound was performed in the BRC-supported Somers Clinical Research Facility at GOSH.
Building the next generation of paediatric research leaders
From early career clinicians to emerging scientists, the NIHR GOSH Biomedical Research Centre (BRC)’s Academic Training Weekend is shaping the future of paediatric research - bringing together talent, expertise and ambition from across the UK.
Bagri family philanthropy enables UCL study into rare childhood neurological condition treated at GOSH
A generous donation from the Bagri family will underpin a landmark study into gene-editing treatments for Dihydropteridine reductase deficiency (DHPR deficiency), an ultra-rare childhood neurological condition, treated at GOSH
Creating communities and lasting involvement
At GOSH, patient and public involvement and engagement (PPIE) builds lasting relationships and communities that shape research over time.
Junior researchers are crucial to the future of paediatric research
Junior researchers are central to the success and sustainability of paediatric research at GOSH and the University College London Institute of Child Health.